An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix

Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet